These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 8807115)

  • 1. Treatment of chronic graft-versus-host disease with ultraviolet irradiation and psoralen (PUVA).
    Vogelsang GB; Wolff D; Altomonte V; Farmer E; Morison WL; Corio R; Horn T
    Bone Marrow Transplant; 1996 Jun; 17(6):1061-7. PubMed ID: 8807115
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Two cases of cutaneous chronic graft versus host disease in treatment with psoralen plus ultraviolet-A-bath photochemotherapy.
    Hoffner MV; Carrizosa Esquivel A; Pulpillo Ruiz A; Herrera Saval A; Conejo-Mir J; Camacho FM
    J Drugs Dermatol; 2009 Nov; 8(11):1027-9. PubMed ID: 19894371
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Photochemotherapy (PUVA) of acute graft-versus-host disease].
    Reinauer S; Lehmann P; Plewig G; Heyll A; Söhngen D; Hölzle E
    Hautarzt; 1993 Nov; 44(11):708-12. PubMed ID: 8276589
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PUVA therapy for chronic cutaneous graft-vs-host disease.
    Jampel RM; Farmer ER; Vogelsang GB; Wingard J; Santos GW; Morison WL
    Arch Dermatol; 1991 Nov; 127(11):1673-8. PubMed ID: 1952971
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral PUVA and topical steroids for treatment of oral manifestations of chronic graft-vs.-host disease.
    Wolff D; Anders V; Corio R; Horn T; Morison WL; Farmer E; Vogelsang GB
    Photodermatol Photoimmunol Photomed; 2004 Aug; 20(4):184-90. PubMed ID: 15238096
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of acute graft-versus-host disease with PUVA (psoralen and ultraviolet irradiation): results of a pilot study.
    Wiesmann A; Weller A; Lischka G; Klingebiel T; Kanz L; Einsele H
    Bone Marrow Transplant; 1999 Jan; 23(2):151-5. PubMed ID: 10197800
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [PUVA therapy for cutaneous acute graft-versus-host disease--a case report].
    Inamitsu T; Inoue M; Akiyoshi H; Honda K; Shibuya T; Nakayama H; Ueda K
    Rinsho Ketsueki; 1995 Nov; 36(11):1321-5. PubMed ID: 8691576
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Eczematoid graft-vs-host disease: a novel form of chronic cutaneous graft-vs-host disease and its response to psoralen UV-A therapy.
    Creamer D; Martyn-Simmons CL; Osborne G; Kenyon M; Salisbury JR; Devereux S; Pagliuca A; Ho AY; Mufti GJ; du Vivier AW
    Arch Dermatol; 2007 Sep; 143(9):1157-62. PubMed ID: 17875877
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PUVA therapy for drug-resistant graft-versus-host disease.
    Atkinson K; Weller P; Ryman W; Biggs J
    Bone Marrow Transplant; 1986 Dec; 1(2):227-36. PubMed ID: 3502781
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prospects for ultraviolet A1 phototherapy as a treatment for chronic cutaneous graft-versus-host disease.
    Calzavara Pinton P; Porta F; Izzi T; Venturini M; Capezzera R; Zane C; Notarangelo LD
    Haematologica; 2003 Oct; 88(10):1169-75. PubMed ID: 14555314
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thalidomide for the treatment of chronic graft-versus-host disease.
    Vogelsang GB; Farmer ER; Hess AD; Altamonte V; Beschorner WE; Jabs DA; Corio RL; Levin LS; Colvin OM; Wingard JR
    N Engl J Med; 1992 Apr; 326(16):1055-8. PubMed ID: 1549151
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Response to thalidomide therapy in refractory chronic graft-versus-host disease.
    Browne PV; Weisdorf DJ; DeFor T; Miller WJ; Davies SM; Filipovich A; McGlave PB; Ramsay NK; Wagner J; Enright H
    Bone Marrow Transplant; 2000 Oct; 26(8):865-9. PubMed ID: 11081386
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Extracorporeal photochemotherapy for the treatment of graft-versus-host disease.
    Rossetti F; Dall'Amico R; Crovetti G; Messina C; Montini G; Dini G; Locatelli F; Argiolu F; Miniero R; Zacchello G
    Bone Marrow Transplant; 1996 Nov; 18 Suppl 2():175-81. PubMed ID: 8932825
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PUVA-bath photochemotherapy and isotretinoin in sclerodermatous graft-versus-host disease.
    Ghoreschi K; Thomas P; Penovici M; Ullmann J; Sander CA; Ledderose G; Plewig G; Kolb HJ; Röcken M
    Eur J Dermatol; 2008; 18(6):667-70. PubMed ID: 18955201
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Psoralen and ultraviolet A irradiation (PUVA) as therapy for steroid-resistant cutaneous acute graft-versus-host disease.
    Furlong T; Leisenring W; Storb R; Anasetti C; Appelbaum FR; Carpenter PA; Deeg HJ; Doney K; Kiem HP; Nash RA; Sanders JE; Witherspoon R; Thompson D; Martin PJ
    Biol Blood Marrow Transplant; 2002; 8(4):206-12. PubMed ID: 12014809
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A high-dose pulse steroid regimen for controlling active chronic graft-versus-host disease.
    Akpek G; Lee SM; Anders V; Vogelsang GB
    Biol Blood Marrow Transplant; 2001; 7(9):495-502. PubMed ID: 11669216
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chronic graft-versus-host disease after allogeneic bone marrow transplantation from an unrelated donor: incidence, risk factors and association with relapse. A report from the Japan Marrow Donor Program.
    Ozawa S; Nakaseko C; Nishimura M; Maruta A; Cho R; Ohwada C; Sakamaki H; Sao H; Mori S; Okamoto S; Miyamura K; Kato S; Kawase T; Morishima Y; Kodera Y;
    Br J Haematol; 2007 Apr; 137(2):142-51. PubMed ID: 17391494
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Extracorporeal photopheresis therapy in the management of steroid-refractory or steroid-dependent cutaneous chronic graft-versus-host disease after allogeneic stem cell transplantation: feasibility and results.
    Apisarnthanarax N; Donato M; Körbling M; Couriel D; Gajewski J; Giralt S; Khouri I; Hosing C; Champlin R; Duvic M; Anderlini P
    Bone Marrow Transplant; 2003 Mar; 31(6):459-65. PubMed ID: 12665841
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of cyclosporine and methylprednisolone dose used for prophylaxis and therapy of graft-versus-host disease on survival and relapse after allogeneic bone marrow transplantation.
    Michallet M; Perrin MC; Belhabri A; Molina L; Nicolini F; Tigaud JD; Sotto JJ; Guyotat D; Fière D; Archimbaud E
    Bone Marrow Transplant; 1999 Jan; 23(2):145-50. PubMed ID: 10197799
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Persistence of host dendritic cells after transplantation is associated with graft-versus-host disease.
    Chan GW; Gorgun G; Miller KB; Foss FM
    Biol Blood Marrow Transplant; 2003 Mar; 9(3):170-6. PubMed ID: 12652467
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.